These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 38640165)
21. A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Goemans N; Mercuri E; Belousova E; Komaki H; Dubrovsky A; McDonald CM; Kraus JE; Lourbakos A; Lin Z; Campion G; Wang SX; Campbell C; Neuromuscul Disord; 2018 Jan; 28(1):4-15. PubMed ID: 29203355 [TBL] [Abstract][Full Text] [Related]
22. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy. Goemans N; Vanden Hauwe M; Signorovitch J; Swallow E; Song J; PLoS One; 2016; 11(10):e0164684. PubMed ID: 27737016 [TBL] [Abstract][Full Text] [Related]
23. Exploring the relationship between North Star Ambulatory Assessment and Health Utilities Index scores in Duchenne muscular dystrophy. Audhya I; Rogula B; Szabo SM; Feeny D; Bolatova T; Gooch K Health Qual Life Outcomes; 2023 Jul; 21(1):76. PubMed ID: 37468890 [TBL] [Abstract][Full Text] [Related]
32. Association between neurodevelopmental impairments and motor function in Duchenne muscular dystrophy. Thangarajh M; McDermott MP; Guglieri M; Griggs RC Ann Clin Transl Neurol; 2023 Dec; 10(12):2285-2296. PubMed ID: 37804000 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925 [TBL] [Abstract][Full Text] [Related]
35. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial. Shieh PB; Mcintosh J; Jin F; Souza M; Elfring G; Narayanan S; Trifillis P; Peltz SW; Mcdonald CM; Darras BT; Muscle Nerve; 2018 Nov; 58(5):639-645. PubMed ID: 30028519 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial. Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ; JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703 [TBL] [Abstract][Full Text] [Related]
37. Effect of a multicomponent nutritional supplement on functional outcomes for Duchenne muscular dystrophy: A randomized controlled trial. Davidson ZE; Hughes I; Ryan MM; Kornberg AJ; Cairns AG; Jones K; Hutchence M; Sampaio H; Morrison M; Truby H Clin Nutr; 2021 Jul; 40(7):4702-4711. PubMed ID: 34237697 [TBL] [Abstract][Full Text] [Related]
38. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Mayhew AG; Cano SJ; Scott E; Eagle M; Bushby K; Manzur A; Muntoni F; Dev Med Child Neurol; 2013 Nov; 55(11):1046-52. PubMed ID: 23909763 [TBL] [Abstract][Full Text] [Related]
39. Comparison of motor proficiency and functional ambulation in Duchenne muscular dystrophy with healthy peers. Yildiz S; Sahin S; Bulut N; Tunca Yilmaz O; Karaduman AA; Akel BS Somatosens Mot Res; 2020 Dec; 37(4):252-256. PubMed ID: 32583706 [TBL] [Abstract][Full Text] [Related]